OVERVIEW

Tailoring Treatment Plans for Metastatic Hormone-Sensitive Prostate Cancer: Expert Guidance on Applying Clinical Advance to Clinical Practice is organized by Postgraduate Institute for Medicine (PIM). The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Release Date: November 18, 2019
Valid for credit through November 18, 2020

Learning Objectives:
After completing this activity, the participant should be better able to:
• Evaluate and incorporate current best practices and evolving therapeutic combinations aimed at achieving optimal clinical response among individuals with metastatic hormone-sensitive prostate cancer (mHSPC), taking into consideration patient and clinical factors that may influence therapeutic selection and response
• Discuss how the risk and prevalence of the cardiovascular disease among prostate cancer patients play a role in mHSPC treatment and monitoring

Additional details will be posted as soon as information is available.